RenovoRx announces SCRI Oncology partners enrolling patients for trial

RenovoRx (RNXT) announced that SCRI Oncology Partners in Nashville, TN, is now enrolling patients with locally advanced pancreatic cancer, LAPC, in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial. SCRI Oncology Partners joins esteemed clinical sites throughout United States participating in the study. The TIGeR-PaC study is using RenovoRx’s TAMP, Trans-Arterial Micro-Perfusion, therapy platform to evaluate the Company’s first investigational drug-device combination product candidate. TAMP utilizes pressure-mediated delivery of gemcitabine to the target tumor. The study is comparing treatment with TAMP in LAPC to the current standard-of-care.